US Nuclear/MIFTEC Radical New Fusion Technology Can Produce Medical
Radioisotopes for $10 Billion Market at Half Today's
Cost
Atlanta, GA.
-- March 12th,
2019 -- InvestorsHub
NewsWire -- US
Nuclear Corp. (USTOC:
UCLE)
-
The
National Academies of Sciences warns about
severe shortages of
radioisotopes that are required to diagnose heart disease, cancer,
other health issues, and to treat over half of all
cancers.
-
Radioisotopes
are largely made in only 4 outdated and unreliable nuclear fission
reactors that are all located outside the United States.
-
US Nuclear's partner
MIFTEC
Laboratories,
has developed a revolutionary method using fusion power to
produce large quantities of radioisotopes at about half the cost of
today's outdated and unreliable methods.
-
Critical
"1010"
milestone proving ability to make abundant radioisotopes from
fusion technology recently achieved by MIFTEC at
University of Nevada, Reno National Terawatt Facility
-
US
Nuclear/MIFTEC fusion generators can save countless lives, are
compact for placement in medical facilities, small fraction of the
cost compared to fission reactors, and produce no long-term
hazardous waste.
Medical
isotopes are minute amounts of radioactive substances commonly used
to diagnose and treat cancer, heart disease and a variety of health
issues. Over 40 million procedures using radioisotopes are
performed each year. They are injected into the body to facilitate
those targeted and whole body scans to enable doctors to determine
(without the use of invasive, risky and costly exploratory surgery)
whether the heart and cardiovascular system has adequate blood
flow; whether cancer has spread to a patient's bones or elsewhere;
and to help diagnose gallbladder, kidney, thyroid, nerve, brain
disorders, and more. When delivered into a malignant tumor,
isotopes can kill the cancer cells minimizing damage to nearby
healthy tissue.
Worldwide
shortages of radioisotopes are already impacting the quality of
healthcare globally and
experts warn about the likelihood
of further deterioration until a major new source for supply comes
on line. Because they are largely produced in very expensive and
outdated nuclear fission reactors, the availability of
radioisotopes is susceptible to unexpected shut downs such as the
recent breakdown and closure of the
Lucas Heights radioisotope
producing nuclear reactor in Australia and the permanent closure of
the big
Chalk River NRU Canadian
reactor.
The Journal of Nuclear Medicine Technology says,
"The production of medical isotopes is in crisis and is built on a
house of cards; adequate production is dependent on 5 aging nuclear
reactors that are being stretched beyond their lifetime operational
capacities. In 2008, the president of the Society of Nuclear
Medicine stated that the United States and other countries are not
prepared to adequately deal with a shortage crisis, nor could they
anticipate or prevent additional shortages. Since 2007, as reactor
shutdowns have occurred, nuclear medicine practitioners throughout
North America and Europe,
in particular, have
needed to ration medical isotopes, cancel or postpone procedures,
and pay higher costs for medical isotopes. This has created ethical
problems surrounding beneficent care for patients, and rationing
decisions are frequently being made by individual practitioners who
may not have sufficient knowledge or expertise in effective and
sound priority-setting frameworks."
Now There
is Good News for Cancer and Heart Disease Patients
US Nuclear Corp.'s partner, MIFTEC Laboratories, Inc., has
discovered a revolutionary new way to make commercial quantities of
radioisotopes in their fusion power generators. Their fusion based
method is simple, safe, and cost-effective. It
uses an isotope of hydrogen as fuel, which is derived from seawater
compared to the current method of using highly enriched or low
enriched uranium (HEU/LEU) that results in high-cost handling and
disposal, and has dangerous, long-term radioactive
byproducts.
Jerry Simmons,
MIFTEC CEO says,
"Neutron flux of 1012 is
required to make radioisotopes in commercial quantities, and the
exciting and historic recent achievement of 1010 from
fusion power by Dr. Hafiz Rahman, President and Chief Scientist and
his staff at MIFTEC Labs and the University of Nevada, Reno
National Terawatt Facility, tells us that our scientific
predictions and device will work as designed. MIFTEC's larger and
more powerful machine currently in the design phase is expected to
achieve, and even surpass, the minimum parameter of
1012 for
radiopharmaceutical production."
US Nuclear Corp. and
MIFTEC
signed a definitive agreement which formally names US
Nuclear as the exclusive manufacturer of MIFTEC's revolutionary
medical isotope generators for North
America and Asia, and makes US Nuclear a sales representative for
all MIFTEC products. The agreement also makes US Nuclear a 10%
equity owner in MIFTEC with the potential to increase its
stake in
the near future.
The global
radiopharmaceutical market is currently estimated at $10B USD. With
the ability to produce unlimited supply of high
quality radioisotopes
at about half of today's cost, US Nuclear Corp. & MIFTEC
Laboratories, Inc. plan to be a major market participant upon
reaching final testing and implementation that is estimated at
about 24 months. Because of the enormous unfilled demand, it is
estimated that the $10 billion market would be substantially larger
if a greater supply was available, and larger yet if the price was
lower.
A
press release from US Nuclear
states:
"We are proud of the many
accomplishments reached to date, including:
-
US Patent issue
for radionuclide production using Z- pinch neutron
source.
-
Ongoing
collaborations with the University of California, San Diego and the
University of Nevada, Reno National Terawatt Facility for
laboratory experiments and advancement of MIFTEC technology, and
Oakridge Labs.
And planned
actions:
-
Planned
production of Mo-99 using the safe, efficient, environmentally
friendly and scalable Staged ZPinch technology, producing no
long-term nuclear waste
-
MIFTEC technology
with expected capability of providing the nuclear medicine industry
with on-site isotope production at a cost savings of up to 50% of
current facilities."
US Nuclear is
moving forward and is already
searching for the best
cities to build their first fusion powered generators.
Bob Goldstein,
the CEO of US Nuclear, graduated from MIT with a degree in
Physics and
also has a degree
in Engineering from Stanford. He has authored more than 40
white papers and presentations on radiation measurement and his
work has been met and approved by US Federal standards set by the EPA,
FDA, and NRC. He also works closely with
Los Alamos, Sandia and Jefferson National Labs. His family's first experiences
in
nuclear physics
go back to the 1940's when his
father was involved in the historic Manhattan Project that
developed the atomic bomb.
Mr. Goldstein
founded US Nuclear and is known for delivering the most sensitive,
accurate and reliable instruments in the world. The quality of
their work is confirmed by a list of loyal and repeat customers
such as NASA, the EPA, Department of Energy, U.S. Air Force, U.S.
Army, U.S. Navy, MIT, Pacific Gas & Electric, General Electric,
Lawrence Livermore, Oakridge National Lab and many more.
Strong Growth Underway
US Nuclear has
enjoyed a long-standing financial history of stable sales and
profitability, but in 2017 US Nuclear experienced a strong increase
in demand for its products triggering a sales increase of 50%.
Growth is continuing and appears positioned for substantial
long-term increases as the environmental monitoring market surges
with sales projections
forecast at $20 billion
by 2021. For example, China is converting all of
their
coal-fired power plants that are responsible for dangerous polluted
air and water, to about 200 fission nuclear reactors that all
require the best radiation monitoring equipment in order to insure
safety. The Chinese nuclear agency claims that each individual
nuclear power plant requires about $8,000,000 in the highest
quality and most reliable radiation monitoring devices and has
already met with Mr. Goldstein twice in 2018 with the intention of
purchasing large orders of US Nuclear monitoring equipment. With
World Nuclear Power Organization's
forecast for a growing
number of nuclear power plants to produce electricity (none planned
to produce radioisotopes), the demand for radiation monitoring
devices also grows.
Other
large opportunities for US Nuclear are their unique products
recently offered for radon mitigation in homes and offices and the
use of drones to mount their sophisticated monitoring devices.
Radon is commonly found in many homes and is one of the leading
known causes of lung cancer. Goldman Sachs sees the
drone market growing
to a very large size by 2020.
The
environmental monitoring market all by itself represents
significant growth opportunities to US Nuclear, but the
radioisotope opportunity is one that could set US Nuclear apart
from many other growth opportunities.
Three large companies in the
medical imaging space that can benefit from the enormous, low cost,
supply of radioisotopes from US Nuclear/MIFTEC are:
Lantheus
Holdings,
Inc. (LNTH), Cardinal Health, Inc. (CAH), and General
Electric Company (GE)
In
conclusion, US Nuclear is enjoying strong growth from its core
business, and on top of that, is well positioned to become a
dominant supplier in a multi-billion-dollar healthcare market of
radioisotopes.
Goldstein
says,
"Given the failing state of essential medical isotope production
facilities, this
first-ever achievement to meet and exceed the 1010
milestone
in fusion neutron production could not come at a better time.
Additionally, the projected cost savings of up to 50% over the
current imported resources; the idea of on-site production; the low
cost and shorter time to build the generators, and the
environmental benefit of a non-proliferating process that precludes
the hazards of fission-based methods; should make for important
upgrades ahead in the vital medical isotope supply chain."
Without including the immense
potential for the multi-billion-dollar radioisotope opportunity and
just based on established and growing sales of existing products
close to $4 million currently, in combination with a very small
market cap of under $10 million comprised of only 17 million shares
outstanding (over 10 million of those shares tightly held by
management), Emerging MicroCaps finds US Nuclear shares
($.50) are highly undervalued and targets 12-month and 24-month
prices for US Nuclear at $3.00 and $8.00 respectively. If the
radioisotope opportunity occurs as management is pursuing, US
Nuclear Corp. share price could attain numbers matching FANG stock
performances.
Contact:
US Nuclear
Corp. (UCLE)
March 12,
2019
Emerging
MicroCaps
Atlanta,
GA
EmergingMicroCaps.com